Evolution of Spine Surgery Market is Changing the Landscape

The global market for spine surgery devices was estimated to be worth about $12.43 billion in 2010, and is forecast to reach approximately $23.90 billion by 2020, exhibiting a compound annual growth rate (CAGR) of 6.96% (2011-2020). The device segments comprising this total are:

Posterior Pedicle Screw Fusion Systems
Anterior Cervical Plate Systems
Anterior Thoracolumbar Plate Systems
Anterior Lumbar Interbody Fusion (ALIF) devices
Transforaminal Lumbar Interbody Fusion (TLIF) devices
Posterior Lumbar Interbody Fusion (PLIF) devices
Axial Lumbar Interbody Fusion (AxiaLIF) devices
Interspinous Process Spacer (ISP)
Cervical Artificial Discs
Lumbar Artificial Discs
Vertebroplasty
Balloon Kyphoplasty
Allografts
Demineralized Bone Matrix (DBM)
Bone Morphogenetic Proteins (BMPs)

This growth will be driven by a number of factors, including:

The ageing population worldwide
Increasing incidence of obesity
A growing middle class in developing countries, with the ability to pay out of pocket for spine surgery
Improving worldwide economy
Technological device enhancements, leading to improved surgical results
Developments in minimally invasive spine surgery (MISS) devices driving a strong increase in MISS, with its numerous advantages
In the US, improvements in reimbursement as clinical trials demonstrate the efficacy of treatments using the devices
US healthcare reform leading to medical insurance coverage for more people, allowing those suffering from intractable back pain to receive surgical treatment

As a result of aggregate growth and the differential growth rates of specific spine surgery product types, the landscape of spine surgery will change from 2011 to 2020. Although the aggregate growth is just under 7%, this is the net effect of all growth rates that range, individual product segments, from a decline of 5% in CAGR to an increase of over 30% CAGR.

Global Spine Surgery Market by Product Type, 2011 & 2020

Source: “Worldwide Spine Surgery: Products, Technologies, Markets and Opportunities, 2010-2020″, Report #M520, MedMarket Diligence, LLC.

Author

PatrickDriscoll

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

View all posts by PatrickDriscoll

Where Is The Balance? Pushing Back Against Consumer Health Tech

Larry Alton - August 18, 2017

When Republican Congressman Jason Chaffetz glibly remarked that Americans struggling to afford insurance should choose between that and their smartphones,…